

Yannick Le Meur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1875136/publications.pdf>

Version: 2024-02-01

82
papers

5,744
citations

81900

39
h-index

76900

74
g-index

86
all docs

86
docs citations

86
times ranked

5595
citing authors

#	ARTICLE	IF	CITATIONS
1	An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 825-839.	0.7	44
2	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	4.7	5
3	Impact of targeted hypothermia in expanded-criteria organ donors on recipient kidney-graft function: study protocol for a multicentre randomised controlled trial (HYPOREME). <i>BMJ Open</i> , 2022, 12, e052845.	1.9	1
4	HEMO ₂ life [®] improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study. <i>Artificial Organs</i> , 2022, 46, 597-605.	1.9	10
5	Is COVID-19 infection more severe in kidney transplant recipients?. <i>American Journal of Transplantation</i> , 2021, 21, 1295-1303.	4.7	190
6	Among CMV ⁺ positive renal transplant patients receiving non ^T cell depleting induction, the absence of CMV disease prevention is a safe strategy: A retrospective cohort of 372 patients. <i>Transplant Infectious Disease</i> , 2021, 23, e13541.	1.7	1
7	Abdominal multi-organ segmentation with cascaded convolutional and adversarial deep networks. <i>Artificial Intelligence in Medicine</i> , 2021, 117, 102109.	6.5	59
8	Clinical Utility of Biochemical Markers for the Prediction of COVID-19 [~] Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
9	Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic. <i>Nephrologie Et Therapeutique</i> , 2021, 17, 245-251.	0.5	8
10	Selection of <i>Pneumocystis jirovecii</i> Inosine 5 ² -Monophosphate Dehydrogenase Mutants in Solid Organ Transplant Recipients: Implication of Mycophenolic Acid. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 849.	3.5	1
11	Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 647-653.	2.9	1
12	Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. <i>Transplantation Proceedings</i> , 2020, 52, 3179-3185.	0.6	3
13	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	5.2	213
14	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	5.2	85
15	First-in-human use of a marine oxygen carrier (M101) for organ preservation: A safety and proof-of-principle study. <i>American Journal of Transplantation</i> , 2020, 20, 1729-1738.	4.7	44
16	Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. <i>Kidney International</i> , 2020, 98, 476-487.	5.2	38
17	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de ^{Novo} kidney transplant patients. <i>Kidney International</i> , 2019, 96, 231-244.	5.2	69
18	Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019, 36, 462-477.	2.9	25

#	ARTICLE	IF	CITATIONS
19	REPRISE: tolvaptan in advanced polycystic kidney disease. <i>Kidney International</i> , 2018, 93, 292-295.	5.2	6
20	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. <i>American Journal of Human Genetics</i> , 2018, 102, 832-844.	6.2	208
21	Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 645-652.	0.7	31
22	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney International</i> , 2018, 94, 1217-1226.	5.2	20
23	PKD2 -Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis. <i>American Journal of Kidney Diseases</i> , 2017, 70, 476-485.	1.9	50
24	Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. <i>American Journal of Transplantation</i> , 2016, 16, 2181-2186.	4.7	52
25	Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study. <i>Transplant International</i> , 2016, 29, 23-33.	1.6	12
26	Mutations in GANAB , Encoding the Glucosidase III β Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. <i>American Journal of Human Genetics</i> , 2016, 98, 1193-1207.	6.2	345
27	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 648-659.	1.9	78
28	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.7	206
29	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. <i>Pharmacogenomics</i> , 2016, 17, 375-391.	1.3	13
30	The PROPKD Score. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 942-951.	6.1	245
31	Can ultrasound kidney length qualify as an early predictor of progression to renal insufficiency in autosomal dominant polycystic kidney disease?. <i>Kidney International</i> , 2015, 88, 1449.	5.2	0
32	Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. <i>Journal of Autoimmunity</i> , 2015, 61, 54-61.	6.5	23
33	What immunosuppression should be used for old-to-old recipients?. <i>Transplantation Reviews</i> , 2015, 29, 231-236.	2.9	16
34	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv26-iv32.	0.7	11
35	Genetics and Pathogenesis of Autosomal Dominant Polycystic Kidney Disease: 20 Years On. <i>Human Mutation</i> , 2014, 35, 1393-1406.	2.5	74
36	B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. <i>Kidney International</i> , 2014, 85, 590-599.	5.2	62

#	ARTICLE	IF	CITATIONS
37	Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency. <i>American Journal of Kidney Diseases</i> , 2014, 63, 119-123.	1.9	84
38	Kidney volume—a crystal ball for ADPKD prognosis?. <i>Nature Reviews Nephrology</i> , 2014, 10, 485-486.	9.6	6
39	Type of PKD1 Mutation Influences Renal Outcome in ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1006-1013.	6.1	403
40	Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 74-76.	2.9	10
41	Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 360-368.	6.1	110
42	Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	37
43	Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3651-3659.	0.7	10
44	Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil. <i>Transplantation</i> , 2011, 92, 1244-1251.	1.0	24
45	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011, 25, 58-64.	2.9	65
46	Glomerular Antibodies in Lupus Nephritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 151-158.	6.5	51
47	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 537-543.	1.5	48
48	Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial. <i>Transplantation</i> , 2010, 89, 1255-1262.	1.0	15
49	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 341-358.	4.5	276
50	A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3096-3106.	0.7	22
51	TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2459-2467.	6.1	63
52	Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 805-816.	3.5	117
53	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	2.0	398
54	Which autoantibodies announce that lupus nephritis is on the way?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 287-295.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Renal Involvement in Wegener's Granulomatosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 22-29.	6.5	19
56	CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2024-2032.	0.7	52
57	Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. <i>American Journal of Transplantation</i> , 2007, 7, 2496-2503.	4.7	368
58	A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 477-484.	2.4	48
59	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 51-60.	4.7	91
60	A comparison of the effect of cyclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, .	2.4	0
61	Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 354-361.	2.0	96
62	A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil. <i>Clinical Pharmacokinetics</i> , 2005, 44, 837-847.	3.5	59
63	Serum levels of macrophage-colony stimulating factor (M-CSF): a marker of kidney allograft rejection. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1862-1865.	0.7	27
64	A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. <i>Kidney International</i> , 2004, 65, 2030-2040.	5.2	31
65	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	4.7	171
66	Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 609-619.	2.0	82
67	Blockade of Macrophage Colony-Stimulating Factor Reduces Macrophage Proliferation and Accumulation in Renal Allograft Rejection. <i>American Journal of Transplantation</i> , 2003, 3, 294-300.	4.7	72
68	Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. <i>Transplantation</i> , 2002, 73, 1318-1324.	1.0	42
69	Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. <i>American Journal of Medicine</i> , 2002, 113, 516-519.	1.5	13
70	Gender differences in responsiveness to erythropoietin: In Reply. <i>American Journal of Kidney Diseases</i> , 2002, 39, 443.	1.9	0
71	Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF-containing Triple Therapy. <i>American Journal of Transplantation</i> , 2002, 2, 48-56.	4.7	226
72	Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 805-811.	1.9	71

#	ARTICLE	IF	CITATIONS
73	Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. <i>Journal of Leukocyte Biology</i> , 2002, 72, 530-7.	3.3	54
74	Application of a Gamma Model of Absorption to Oral Cyclosporin. <i>Clinical Pharmacokinetics</i> , 2001, 40, 375-382.	3.5	51
75	Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements. <i>American Journal of Kidney Diseases</i> , 2001, 38, 510-517.	1.9	68
76	The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 442-442.	0.7	4
77	Whole blood production of monocytic cytokines (IL-1 β , IL-6, TNF- α , sIL-6R, IL-1Ra) in haemodialysed patients. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2420-2426.	0.7	34
78	Acute renal failure in a marathon runner: role of glomerular bleeding intubular injury. <i>American Journal of Medicine</i> , 1998, 105, 251-252.	1.5	13
79	Is Plasma Ac-SDKP Level a Reliable Marker of Chronic Angiotensin-Converting Enzyme Inhibition in Hypertensive Patients?. <i>Hypertension</i> , 1998, 31, 1201-1202.	2.7	6
80	DEVELOPMENT OF ENZYMO-IMMUNOASSAYS (EIA) FOR MACROPHAGE COLONY-STIMULATING-FACTOR (M-CSF) AND LEUKAEMIA INHIBITORY FACTOR (LIF) BY USING THE SAME CAPTURE AND SIGNAL GENERATING POLYCLONAL ANTIBODY. <i>Cytokine</i> , 1996, 8, 586-591.	3.2	17
81	Macrophage colony stimulating factor involvement in uremic patients. <i>Kidney International</i> , 1996, 50, 1007-1012.	5.2	24
82	ADMINISTRATION OF AN ANTI-CD11a MONOCLONAL ANTIBODY IN RECIPIENTS OF KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1994, 58, 377-379.	1.0	0